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Abstract 
Ovarian cancer is the third most common cancer in Indonesia after cervical and breast cancer with the increasing 
incidence and mortality. The purpose of this study was to determine the relationship of survivin expression with 
the degree of histopathology and the incidence of metastasis to the omentum using immunohistochemical 
examinations. This is a cross-sectional study using 72 paraffine blocks of serous carcinoma of ovary without and 
with metastasis to omentum in Makassar, Indonesia during 2015-2018. Survivin was positive in tumor cells with 
a different degree based on the grade of histopathology and the incidence of metastases to the omentum. There 
was a significant difference between survivin expression with the degree of histopathology and the incidence of 
metastases to the omentum in serous carcinoma of ovary (p = 0.000). 
Keywords: survivin; serous carcinoma; ovary; metastasis. 
------------------------------------------------------------------------ 
* Corresponding author.  
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2019) Volume 48, No  5, pp 107-113 
 
108 
 
1. Introduction 
Based on data from the American Cancer Society, in 2013 in the United States, the number of new cases of 
ovarian cancer was around 3% or 22,240 cases from 805,500 new cases of malignancy in female reproductive 
organs, and there were about 5% or 14,030 cases of which died from 273,430 cases of death due to cancer in 
women [1]. In 2015, the number of new cases of ovarian cancer was around 2.62% or 21,290 of 810,170 new 
cases of female reproductive organ malignancy, and about 5% or 14,180 cases of 277,280 cases of cancer deaths 
in women [2]. Ovarian cancer increases rapidly in women aged 50-55 years and slowly in women aged over 50 
years [3]. In 2010 the Indonesian Cancer Foundation noted that there were 1156 cases of ovarian cancer and 
ranked eighth in the most common malignancies in Indonesia. In 2013, ovarian cancer ranked third after 
cervical and breast cancer [4]. More than 60% of new cases and around 70% of cancer deaths in the world each 
year occur in Africa, Asia, and Central and South America. It is estimated that annual cancer cases will increase 
from 14 million in 2012 to 22 million in the next two decades. Ovarian cancer metastasis is the spread of cancer 
cells to a place that is not directly related to the primary tumor. The path of spread or metastasis can occur 
through 3 pathways; direct seeding on the surface or cavity, lymphatic pathways, and hematogenous pathways. 
Ovarian cancer patients usually come in advanced stages (with metastasis) which have poor therapy outcomes 
and high mortality rates. Survivin plays a role in tumorigenesis through a variety of mechanisms, including 
angiogenesis and cell motility which have a role in invasion and metastasis. Based on these, we did a study to 
determine survivin expression with grade and event of metastasis in serous carcinoma as the most common type 
of ovarian cancer. 
2. Methods 
2.1.  Case Selection 
This research is a cross-sectional study using paraffine blocks of serous carcinoma of ovary without and with 
metastasis to omentum in Anatomical Pathology Laboratories of DR. Wahidin Sudirohusodo Hospital, 
Hasanuddin University Hospital, and Sentra Diagnostik Patologia, Makassar from 2015-2018. Samples were 
grouped in low-grade non-metastasis, high-grade non-metastasis, low-grade metastasis, and high-grade 
metastasis based on WHO classification. 
2.2.  Survivin Immunohistochemistry 
Immunohistochemical staining used the standard method of protocol from Biocare using concentrated 
polyclonal survivin antibody with dilution 1:50. The results of immunohistochemical staining were scored 
manually using a light microscope by two pathologists. The interpretation of the score is calculated based on the 
staining intensity and percentage of the tumor cells using Allred-like score. (Score 0-1 = negative, 2-3 = weak 
positive, 4-5 = moderate positive, 6-7 = strong positive, and 8-9 = very strong positive). 
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Figure 1: Positive Survivin Expression. (A) Weak, (B) Moderate, (C) Strong, (D) Very Strong. (400X) 
2.3.  Data analysis 
The data were analyzed statistically using the SPSS (Statistical Package for Social Sciences) version 20.0 (IBM 
Company). The relationship of survivin expression with the degree of histopathology and the incidence of 
metastasis to the omentum of serous carcinoma of ovary was analyzed with Oneway Anova and Chi-Square 
tests. 
3. Results 
There were 72 samples of serous carcinoma of ovary, consisted of 9 samples (12.5%) of low-grade non-
metastasis, 15 samples (20.8%) of high-grade non-metastasis, 12 samples (16.7%) of low-grade metastasis, and 
36 samples (50%) of high-grade metastasis. (Table 1) The samples’ age was ranged from 23 to 72 years old with 
a mean and median 49 years old. (Table 2) 
Table 1: General Characteristics 
Characteristics n % 
Serous Carcinoma of 
Ovary 
Low-grade non-Metastasis 
(LGNM) 
9 12.5 
High-grade non-Metastasis 
(HGNM) 
15 20.8 
Low-grade Metastasis (LGM) 12 16.7 
High-grade Metastasis 
(HGM) 
36 50.0 
Survivin Expression 
Weak 4 5.6 
Moderate 10 13.9 
Strong 32 44.4 
Very Strong 26 36.1 
A B 
C D 
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Table 2: Age Characteristic 
 Mean Median Minimum Maximum 
Age (Years) 49.25 49 23 72 
Samples of serous carcinoma of ovary with low-grade non-metastasis, high-grade non-metastasis, low-grade 
metastasis, and high-grade metastasis had age range 44-67, 32-64, 28-68 and 23-72 years old with mean 54, 48, 
47 and 49 years old. These data showed no significant difference in grade and event of metastasis with age 
(Oneway Anova Test; p = 0.375 (p> 0.05)). (Table 3) 
Table 3: Comparison between Serous Carcinoma of Ovary’s Grade and Event of Metastasis to Age 
Characteristic 
Age 
Serous Carcinoma of Ovary 
p-value 
LGNM HGNM LGM HGM 
Mean 54.66 48.00 47.50 49.00 
0.375* 
Median 53.00 47.00 47.50 49.50 
Minimum 44.00 32.00 28.00 23.00 
Maximum 67.00 64.00 68.00 72.00 
* Oneway Anova Test 
Serous carcinoma of ovary had weak-strong positive survivin expression for low-grade non-metastasis, and 
high-grade non-metastasis, moderate-strong positive for low-grade metastasis, and strong-very strong positive 
for high-grade metastasis. Weak positive survivin expression was in non-metastasis (75% in low-grade and 25% 
in high-grade), and very strong positive was only in high-grade metastasis (100%). These data showed a 
significant difference of survivin expression with grade and event of metastasis (Chi-Square Test; p = 0.000 (p< 
0.05)). (Table 4) 
Table 4: Comparison between Survivin Expression with Serous Carcinoma of Ovary’s Grade and Event of 
Metastasis 
Serous Carcinoma 
of Ovary 
Survivin Expression 
p-value Weak Moderate Strong Very Strong 
n % n % n % n % 
LGNM 3 75 3 30 3 9.4 0 0.0 
0.000* 
HGNM 1 25 6 60 8 25 0 0.0 
LGM 0 0 1 10 11 34.4 0 0.0 
HGM 0 0 0 0 10 31.3 26 100 
*Chi-Square Test 
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4. Discussion 
Ovarian cancer usually occurs in women aged 45 to 65 years old. It is 3% of malignancies that occur in women 
and the fifth leading cause of death from cancer in the United States. According to The American Cancer 
Society, the number of new cases of ovarian cancer in 2013 in the United States was around 3% or 22,240 cases 
out of 805,500 new cases of cancer and 5% or 14,030 cases of them died from 273,430 cases of cancer deaths in 
women [1]. In 2015, the number of new cases of ovarian cancer was about 2.62% or 21,290 of 810,170 new 
cases and 5% or 14,180 cases of 277,280 cases of cancer deaths in women [2]. Based on research in 
histopathology, molecular and genetic, carcinogenesis of ovarian cancer is divided into 2 categories called type 
1 and type 2. Low-grade serous carcinoma (type 1) is characterized by a lack of genetic mutations, mutations in 
ERBB2 occur in less than 5% of tumors. Mutations in KRAS and BRAF are found both in serous borderline 
tumors. This shows that KRAS and BRAF mutations occur early in tumorigenesis, even before the development 
of serous borderline tumors. Oncogenes such as KRAS, BRAF, and ERBB2 are regulators of mitogen-activated 
protein kinase (MAPK) and mutations in this gene result in the activation of the MAPK signal transduction 
pathway, which results in uncontrolled cell proliferation [5]. High-grade serous carcinoma (type 2) is usually 
found at an advanced stage and rapidly developed. At the molecular level, high-grade serous carcinoma shows 
TP53 gene mutations in 80% of cases and has a high Ki67 proliferation index (between 50-75%). Over-
expression of HER2/neu is also found in 20-67% of cases, AKT activation in 12-30% of cases, and p16 
inactivation in 15% of cases. About 10-15% of ovarian cancers are hereditary [5,6]. Table 2 shows that the 
average age of patients when diagnosed with ovarian cancer ranged from 23 years to 72 years with a median of 
49 years. This is in line with epidemiological studies that state that ovarian malignancies occur in the fourth 
decade of a woman's life [8]. This can also be related to the incidence of menopause at that age. Menopause is 
defined as the permanent cessation of menstruation for 1 year and physically correlates with decreased estrogen 
secretion resulting from the loss of follicular function [9]. Menopause occurs in women aged between 45 and 55 
years worldwide [10]. Table 4 shows a significant difference in survivin expression between groups with 
different grades and events of metastasis; low-grade non-metastasis, high-grade non-metastasis, low-grade 
metastasis, and high-grade metastasis. It indicates that survivin plays a role in ovarian cancer tumorigenesis and 
can be used as a prognostic biomarker. This supports the role of survivin in the process of carcinogenesis as 
apoptotic inhibitors, mitotic regulators, angiogenesis, and cell movement [11]. Based on the study conducted by 
Kurosaki and his colleagues that the level of survivin expression is highly correlated with the clinical stage, 
tumor stage, and histopathological grading which shows superior accuracy for detecting ovarian cancer [12]. 
The degree of histopathology is influenced by cell proliferation and mitotic activity. There are several pathways 
for the role of survivin in their effects on the carcinogenesis process in serous carcinoma of ovary, in this case 
especially in the high-grade group. In high-grade, it has very fast growth, a very aggressive tumor and has a 
high-grade nucleus, which is associated with its mitotic figure. High-grade cancer has characteristics of TP53 
and genetic mutations that are very unstable [13]. Survivin is also able to perform the role of metastasis because 
of the process of angiogenesis. Metastasis is influenced by the ability of cells to invade, enter the bloodstream, 
adhesion, extravasation, growth, and angiogenesis. Based on the study conducted by Lv and his colleagues 
2010, survivin triggering angiogenesis seems to be related to its ability to maintain the integrity of the 
microtubule structure and inhibit apoptosis in endothelial cells needed for viability and cytoprotective 
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endothelial cells. Alternatively, in tumors with few endothelial cells, survivin triggers VEGF synthesis/release 
encouraging vasculogenic-mimicry [14,15]. For ovarian cancer, the most common site of metastasis is omentum 
[16]. Based on the study conducted by Altieri and his colleagues 2014, Jaiswal 2015, and Di Palma and his 
colleagues 2013, survivin mRNA expression is associated with prognostic factors, such as the clinical stage of 
the tumor, the degree of histopathology or lymph involvement and this correlation is associated with the 
development of ovarian cancer. The moreover survivin expression, the worse the prognosis is [17,18,19,20] . In 
the high-grade metastasis serous carcinoma of ovary group, there were very strong positive survivin 
expressions, and in the non-metastatic low grade and non-metastatic high-grade group, there were weak positive 
expressions. This shows a significant relationship between survivin expression with the degree of 
histopathology and angiogenesis that is associated with the grade of histopathology and the incidence of 
metastasis [21,22]. 
5. Consluison 
From the results of this study, it can be concluded as follows; the higher the expression of survivin, the higher 
the histopathological grade of serous carcinoma of ovary, and the higher the incidence of metastasis to 
omentum. So that survivin can be used as a prognostic biomarker, especially for high-grade metastasis serous 
carcinoma of ovary, which shows a very strong survivin expression.  
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